(1-tritylindazol-3-yl)methanol | 1186507-43-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (1-tritylindazol-3-yl)methanol
• CAS: 1186507-43-6
• 化学式: C₂₇H₂₂N₂O
• 分子量: 390.484
• InChiKey: ITEDNMOIBNOTDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  氯仿 、 (1-tritylindazol-3-yl)methanol 、 丙酮 在 sodium hydroxide 、 盐酸 、 水 作用下， 生成 2-((1-tritylindazol-3-yl)methoxy)-2-methylpropanoic acid
  参考文献：
  名称：

  [EN] 1-BENZYL-3-HYDROXYMETHYLINDAZOI?E DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
  [FR] NOUVEAUX DÉRIVÉS DE 1-BENZYL-3-HYDROXYMÉTHYLINDAZOLE ET LEUR UTILISATION DANS LE TRAITEMENT DES MALADIES BASÉES SUR L'EXPRESSION DE MCP-1, CX3CR1 ET P40

  摘要：

  公开号：

  WO2009109613A3
• 作为产物：
  描述：

  isobutyl 1-tritylindazole-3-carboxylate 在 lithium aluminium tetrahydride 、 水 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 (1-tritylindazol-3-yl)methanol
  参考文献：
  名称：

  [EN] 1-BENZYL-3-HYDROXYMETHYLINDAZOI?E DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
  [FR] NOUVEAUX DÉRIVÉS DE 1-BENZYL-3-HYDROXYMÉTHYLINDAZOLE ET LEUR UTILISATION DANS LE TRAITEMENT DES MALADIES BASÉES SUR L'EXPRESSION DE MCP-1, CX3CR1 ET P40

  摘要：

  公开号：

  WO2009109613A3

文献信息

• NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40
  申请人：GUGLIELMOTTI Angelo

  公开号：US20110160205A1

  公开（公告）日：2011-06-30

  The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

  本发明涉及一种新颖的1-苄基-3-羟甲基吲唑衍生物，其结构式（I）如权利要求书所述，并且涉及包含它们的制药组合物，以及与药学上可接受的载体一起使用。此外，本发明还涉及1-苄基-3-羟甲基吲唑衍生物的使用，用于制备在基于MCP-1、CX3CR1和p40的表达的疾病治疗中具有活性的制药组合物，并且用于治疗或预防基于MCP-1、CX3CR1和p40的表达的疾病的方法。
• 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
  申请人：Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.

  公开号：US08283348B2

  公开（公告）日：2012-10-09

  The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

  本发明涉及一种新型的1-苄基-3-羟甲基吲唑衍生物，其公式如（I）所述，并且涉及包含它们的制药组合物，以及与药学上可接受的载体一起使用。此外，本发明还涉及使用1-苄基-3-羟甲基吲唑衍生物制备具有活性的制药组合物，用于治疗基于MCP-1、CX3CR1和p40表达的疾病，并且涉及将它们用于治疗或预防基于MCP-1、CX3CR1和p40表达的疾病的方法。
• 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40
  申请人：Guglielmotti Angelo

  公开号：US08835481B2

  公开（公告）日：2014-09-16

  The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to Formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

  本发明涉及一种新型1-苄基-3-羟甲基吲唑衍生物，其符合权利要求书中所述的公式（I），以及包含它们的制药组合物和与其一起使用的药用载体。此外，本发明还涉及使用1-苄基-3-羟甲基吲唑衍生物制备对基于MCP-1、CX3CR1和p40表达的疾病具有活性的制药组合物，并将其用于治疗或预防基于MCP-1、CX3CR1和p40表达的疾病的方法。
• 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40
  申请人：Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.

  公开号：EP3181551A1

  公开（公告）日：2017-06-21

  The present invention relates to 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle, for use in the treatment of diseases based on the expression of CX3CR1 and p40.

  本发明涉及权利要求中所述的式(I)的1-苄基-3-羟甲基吲唑衍生物，以及由它们和药学上可接受的载体组成的药物组合物，用于治疗基于CX3CR1和p40表达的疾病。
• 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
  申请人：Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.

  公开号：EP2254870B1

  公开（公告）日：2016-02-24